Vanguard Group Inc Lineage Cell Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,600,995 shares of LCTX stock, worth $4.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,600,995

Previous 8,473,967 1.5%

Holding current value

$4.82 Million

Previous $8.47 Million 7.64%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.8 - $1.12 $101,622 - $142,271	127,028 Added 1.5%	8,600,995 $7.83 Million
Q2 2024 Aug 13, 2024	BUY	$0.89 - $1.47 $89,174 - $147,288	100,196 Added 1.2%	8,473,967 $8.47 Million
Q1 2024 May 10, 2024	SELL	$0.86 - $1.48 $9,387 - $16,155	-10,916 Reduced 0.13%	8,373,771 $12.4 Million
Q4 2023 Feb 14, 2024	BUY	$0.91 - $1.35 $65,843 - $97,679	72,355 Added 0.87%	8,384,687 $9.14 Million
Q3 2023 Nov 14, 2023	BUY	$1.16 - $1.53 $1.33 Million - $1.76 Million	1,150,633 Added 16.07%	8,312,332 $9.81 Million
Q2 2023 Aug 14, 2023	BUY	$1.26 - $1.53 $827,518 - $1 Million	656,761 Added 10.1%	7,161,699 $10.1 Million
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $477,460 - $608,762	397,884 Added 6.52%	6,504,938 $9.76 Million
Q4 2022 Feb 10, 2023	BUY	$1.02 - $1.5 $158,672 - $233,341	155,561 Added 2.61%	6,107,054 $7.15 Million
Q2 2022 Aug 12, 2022	SELL	$1.12 - $1.61 $6,090 - $8,755	-5,438 Reduced 0.09%	5,951,493 $9.4 Million
Q1 2022 May 13, 2022	SELL	$1.21 - $2.48 $5,716 - $11,715	-4,724 Reduced 0.08%	5,956,931 $9.17 Million
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $9,238 - $13,456	5,021 Added 0.08%	5,961,655 $14.6 Million
Q3 2021 Nov 12, 2021	SELL	$2.26 - $2.86 $999,329 - $1.26 Million	-442,181 Reduced 6.91%	5,956,634 $15 Million
Q2 2021 Aug 13, 2021	BUY	$2.17 - $3.0 $13.9 Million - $19.2 Million	6,398,815 New	6,398,815 $18.2 Million

Others Institutions Holding LCTX

# of Institutions

120

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $95.1M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Lineage Cell Therapeutics, Inc. Transaction History